Loading clinical trials...
Loading clinical trials...
Evaluation of First-Trimester Maternal Serum Resistin in Hyperemesis Gravidarum
This cross-sectional case-control study was conducted in Tuzla State Hospital Obstetrics Clinic in Turkey. The study evaluated 400 pregnant women during their first trimester of pregnancy. Many pregnant women (50-90%) experience nausea and vomiting during their first trimester; however, some patients have a disease called "hyperemesis gravidarum" (HG) characterized by very severe nausea and vomiting that may require hospitalization. resistin" is a peptide which is secreted primarily by human adipocytes and mononuclear cells. Evidence suggests that resistin increases plasma glucose concentration, reduces glucose intake by adipocytes, and promotes insulin resistance. Considering the HG effect on endocrinologic and metabolic complications, we hypothesized that resistin levels in maternal serum may change in the presence of HG; therefore, the aim of the present study was to evaluate these resistin levels during the first trimester and their correlation with HG severity.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
Yes
Kartal Dr Lutfi Kirdar City Hospital
Kartal, Istanbul, Turkey (Türkiye)
Start Date
December 15, 2022
Primary Completion Date
March 15, 2023
Completion Date
June 1, 2023
Last Updated
January 3, 2025
210
ACTUAL participants
Resistin
DIAGNOSTIC_TEST
Lead Sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
NCT06896799
NCT06867861
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06836843